Novel Lipoprotein (a) Therapies: A Comprehensive Review
Ugochukwu Ebubechukwu, Onyinye Ugoala, Rameen Shahid, Anandita Kulkarni · 2026
Read Novel Lipoprotein (a) Therapies: A Comprehensive Review by Ugochukwu Ebubechukwu, Onyinye Ugoala, Rameen Shahid, Anandita Kulkarni (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13473182.txt.
Description
Purpose of ReviewLipoprotein(a) [Lp(a)] is a genetically determined, independent risk factor for atherosclerotic cardiovascular disease and calcific aortic valve stenosis. Plasma Lp(a) levels are 70–90% heritable, largely unresponsive to lifestyle changes, and poorly controlled with typical lipid-lowering drugs such as statins and PCSK9 inhibitors.
Catalog record
| CREATOR | Ugochukwu Ebubechukwu, Onyinye Ugoala, Rameen Shahid, Anandita Kulkarni |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 55 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |